Cefdinir 125mg Dispersible Tablets
Cefdinir 250mg Dispersible Tablets
Cefdinir binds to one or more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Absorption: Maximum plasma concentrations occur 2 to 4 hours after an oral dose of Cefdinir.
Bioavailability: 16% to 21% for the capsules and 25% for the oral suspension
Distribution: Widely distributed
Protein binding: 60% to 70% bound to plasma proteins
Metabolism: Undergoes minimal metabolism
Excretion: Via renal excretion. Renal dysfunction reduces the clearance of Cefdinir and results in the need to reduce dosing frequency. No dosage adjustment is needed in patients with hepatic impairment
Half-life: 2.2 ± 0.6 hrs after a 7mg/kg dose and 1.8 ± 0.4 hrs after a 14 mg/kg dose
Pneumonia, Bronchitis, Otitis Media, Tonsillitis/ Pharyngitis, Sinusitis, Skin & Structure Infection
The recommended dose for Cefdinir in children is 7mg/kg twice daily or 14mg/kg once daily and for adult is 300mg twice daily for 5-10 days.
Diarrhea, rash, vomiting, oral thrush, abdominal pain, vaginitis or vaginal moniliasis or leukopenia
Hypersensitivity to cephalosporin.
Penicillin-sensitive patients; superinfection; seizure; pseudomembranous colitis; pregnancy, lactation; renal or hepatic insufficiency.
Concomitant admin with antacids and Fe reduce the rate and extent of absorption.
Probenecid reduces renal elimination.
Antacids reduce rate and extent of absorption